Skip to content

Clinical trials

Phase 1/2 Melanoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Melanoma Phase: Phase 1/2 Country / region: United States Clear all

279 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20013
20025
20036
20045
20057
200611
20078
20084
20097
20109
20116
20127
20137
201412
201519
201615
201713
201818
201911
202016
202119
202216
202314
202410
202511
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed115
Terminated65
Recruiting49
Active, not recruiting24
Withdrawn12
Unknown status11
Suspended3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)21
M.D. Anderson Cancer Center13
Craig L Slingluff, Jr7
Novartis Pharmaceuticals7
Incyte Corporation6
H. Lee Moffitt Cancer Center and Research Institute5
Incyte Biosciences International Sàrl5
Merck Sharp & Dohme LLC5
Bristol-Myers Squibb4
Fred Hutchinson Cancer Center4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Melanoma279
Carcinoma, Non-Small-Cell Lung70
Neoplasm Metastasis47
Neoplasms43
Carcinoma, Renal Cell39
Squamous Cell Carcinoma of Head and Neck38
Colorectal Neoplasms30
Ovarian Neoplasms30
Stomach Neoplasms27
Breast Neoplasms23

Trials

Showing 1 to 25 of 279. Each trial links to its page on Pharma Observatory.

179 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.